Phase 1 N=16 A Study of Evacetrapib and Digoxin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Digoxin — 1.75; 2.15 nanograms/milliliter (ng/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=150 Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
HIV-1 Infection · HCV Infection
Primary: Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12) — 98.6; 95.8 percentage of participants — p=0.002
Phase 4 N=267 Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Functional Residual Capacity (FRC) After 4 Weeks of Treatment — -0.162; -0.037 Liters — p=0.069
Phase 1 N=24 A Study of Evacetrapib in Japanese and Non-Japanese Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Pravastatin — 142; 128 nanograms/milliliter (ng/mL)
N/A N=120 Decision Aid for Therapeutic Options In Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale
N/A N=16 Treatment Modification to Reduce Symptom Burden in Hemodialysis
End Stage Renal Disease
Primary: Number of Participants Recruited, Consented, Randomized and Completed — 51; 16; 16; 16 Participants
Early Phase 1 N=10 Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Type 1 Diabetes
Primary: Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12 — -4.31 Percent change from Baseline
Phase 2 N=70 Management of Insomnia in Breast Cancer Patients
Insomnia · Fatigue
Primary: Insomnia Severity Index (ISI) — 16.3; 14.6; 13.5; 12.1 units on a scale
Phase 3 N=35 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Hemodialysis · Hyperphosphatemia
Primary: Incidence of Adverse Events — 28 Participants
N/A N=50 The Effects of Hydromorphone on Responses to Verbal Tasks
Healthy
Primary: Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire — 7.41; 14.75; 28; 5.76…
Phase 1 N=14 A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation
Japanese Healthy Adult Male Participants
Primary: AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-536 — 6053.7; 6479.6 hour*nanogram per milliliter (h*ng/mL)
N/A N=20 Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Mindfulness · Complementary Medicine
Primary: Global Response Assessment (GRA) — 2; 0; 1; 3 participants
N/A N=33 Balance Training for Elders With Heart Failure
Heart Failure
Primary: Pre/Post Scores on the 30 Second Sit to Stand Test Will be Used to Detect Any Changes in Leg Strength and Endurance That Occur During the 12 Week Group Exercise…
Phase 3 N=91 RISE Pediatric Medication Study
Prediabetes · Type 2 Diabetes
Primary: ß-cell Response Measured by Hyperglycemic Clamp — 4.82; 4.18; 6.92; 5.95 nmol/L — p=>0.05
N/A N=220 Comparative Effectiveness of Acute Low Back Pain Management
Low Back Pain
Primary: Oswestry Disability Index — 9.8; 6.6 units on a scale